Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron   – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 -- Alterity Therapeutics , a...

Related Keywords

Melbourne ,Victoria ,Australia ,Boston ,Massachusetts ,United States ,California ,San Francisco ,Remy Bernarda ,Hannah Howlett ,David Stamler ,National Institute Of Neurological Disorders ,National Institutes Of Health ,Nasdaq ,Alterity Therapeutics ,European Commission ,Securities Exchange ,World Orphan Drug Congress United States ,New Evidence Indicates ,Iron Chaperone ,Redistribute Iron ,Unique Iron Targeting Drug ,Treating Friedreich ,Ashley Pall ,Pharmaceutical Sciences ,Wayne State ,Chief Executive Officer ,Multiple System ,Multiple System Atrophy ,National Institutes ,National Institute ,Neurological Disorders ,Media Contacts ,Securities Act ,Securities Exchange Act ,Annual Report ,Markets ,